carisbamate ykp proposed trade name comfyde experimental anticonvulsant drug development johnson johnson pharmaceutical research development never marketed phase ii clinical trial treatment partial seizures demonstrated compound efficacy treatment partial seizures good safety profile since late compound undergoing large multicenter phase iii clinical trial treatment partial seizures mechanism action doubleblind placebocontrolled trial carisbamate patients migraine determined carisbamate well tolerated doses mgday failed demonstrate drug sufficiently effective placebo migraine compound inlicensed sk corp currently life science business division sk holdings south korean company october johnson johnson announced submitted new drug application us food drug administration fda johnson johnson received provisional approval fda market carisbamate brand name comfyde however august johnson johnson reported fda failed give marketing approval httpsenwikipediaorgwikicarisbamate